Survey: biotechs adapting to COVID-19 era, optimistic about 2021

As biotechs look ahead to 2021, they may not see an end to the pandemic but they are optimistic that virtually all business activities will rebound to some extent, reflecting a net positive outlook.

A survey of 73 companies, mostly biotechs and CROs, conducted by BioCentury and McKinsey & Co. from June 17 to June 30, finds many are taking action to adjust clinical trials to pandemic conditions, with a doubling of the number of respondents adopting digital technologies since the pandemic started. The broad movement raises hope that clinical development will face fewer disruptions next year...